

1

2

3

4

5

6

7

8

9

10

11

**Nominated Activities for the Local Lymph Node Assay (LLNA):
ICCVAM Preliminary Assessment and Recommendations**

TABLE OF CONTENTS

		Page Number
11		
12		
13	1.0 Introduction.....	1
14	2.0 Nominated Activity: Assessment of the Validation Status of the Local	
15	Lymph Node Assay (LLNA) as a Stand-Alone Assay for Potency	
16	Determinations	2
17	3.0 Nominated Activity: Assessment of the Validation Status of Non-	
18	Radioactive LLNA Protocols	7
19	4.0 Nominated Activity: Assessment of the Validation Status of the LLNA	
20	to test mixtures, aqueous solutions and metals.....	14
21	5.0 Nominated Activity: Assessment of the Validation Status of the LLNA	
22	limit test	19
23	6.0 Summary.....	21

1.0 INTRODUCTION

The Interagency Coordinating Committee for the Validation of Alternative Methods (ICCVAM) previously evaluated the validation status of the murine Local Lymph Node Assay (LLNA) as a stand-alone alternative method to the Guinea Pig Maximization Test (GPMT) and the Buehler Assay (NIH publication No. 99-4494; available at <http://iccvam.niehs.nih.gov/methods/immunotox/llna.htm>). As a result of this evaluation, ICCVAM recommended the LLNA as a valid substitute for the guinea pig methods, for most testing situations. Subsequently, the LLNA was accepted within the United States by the Environmental Protection Agency, the Food and Drug Administration, and the Consumer Product Safety Commission (CPSC). In addition, an OECD Test Guideline (OECD TG 429) for the LLNA has been adopted by the 30 member OECD countries.

In January 2007, CPSC submitted a nomination to the National Toxicology Program Interagency Center for the Evaluation of Alternative Methods (NICEATM) (<http://iccvam.niehs.nih.gov/SuppDocs/submission.htm> - nomination) requesting that ICCVAM assess the validation status of:

- the LLNA as a stand-alone test for potency determinations (including severity) for the purpose of hazard classification;
- LLNA protocols that do not require the use of radioactive materials;
- the LLNA cut-down or "limit dose" procedure;
- the ability of the LLNA to test mixtures, aqueous solutions, and metals;
- the current chemical applicability domain of the LLNA.

On January 24, 2007, ICCVAM unanimously endorsed (1) developing performance standards for the LLNA, and (2) initiating a preliminary review of the available data and information associated with the CPSC nominated activities. A determination on which (if any) of the nominated activities will move forward will be made subsequent this review, and consideration of public and SACATM comments on the nominated activities. In anticipation of proceeding with an evaluation of these test methods, ICCVAM and NICEATM are proposing to convene a Panel that would review the usefulness and limitations of each of the LLNA protocols listed above. The Panel may also formulate conclusions on the adequacy of

any draft recommended performance standards, any proposed future validation studies, and draft standardized test method protocols.

2.0 NOMINATED ACTIVITY: ASSESSMENT OF THE VALIDATION STATUS OF THE LLNA AS A STAND-ALONE ASSAY FOR POTENCY DETERMINATIONS

2.1 Background

Based on the recommendations of ICCVAM and an independent scientific peer review panel (hereafter, Panel), the LLNA is now accepted as an alternative to the guinea pig maximization test and the Buehler test for assessing allergic contact dermatitis (ICCVAM 1999)¹. However, the consensus of the Panel was that while the LLNA performed as well as the guinea pig tests for hazard identification of strong to moderate dermal sensitizing agents, it lacked strength in accurately predicting some weak sensitizers. The LLNA is therefore currently considered as a test method that provides quantitative data to support only a determination of the sensitization endpoint (i.e., yes/no decisions).

Although papers have been published showing correlations of dose-potency in animals with human potency, the validation status of such data have not been reviewed according to internationally recognized procedures. For this reason, CPSC recently requested that ICCVAM and NICEATM assess the current validation status of the LLNA as a stand-alone assay for potency determinations (including severity) for classification purposes.

2.2 Preliminary Review

NICEATM conducted a preliminary search² to determine the availability of published data relevant to the use of the LLNA to determine sensitization potency. Upon initial review of the search results, 38 published papers appeared to contain data relevant to the use of LLNA as a stand-alone assay for potency determinations. Based on the listed authors and their affiliations, these papers were published by seven different groups (31 by the groups of Basketter, Gerberick, and Kimber; two by the group of van Loveren; one by the group of

¹Available at: <http://iccvam.niehs.nih.gov/methods/immunotox/immunotox.htm>

²Search terms used and total number of citations identified for each method is provided in Section 2.3. References deemed to be most relevant for this analysis were reviewed further.

DeJong; and one each by the groups of Lalko, Greim, Schlede, and Schneider) and report results on approximately 619 substances. A detailed evaluation and assessment of performance will be prepared and included in a Background Review Document (BRD). Additional searches are ongoing and relevant data will be added to the database.

2.3 References Obtained During Preliminary Review

Search terms used:

PubMed: ("local lymph node" OR LLNA OR "Local Lymph Node" OR "Local lymph node") AND (potency OR potential) - 195 citations returned

Basketter DA and Kimber I. 2006. Predictive tests for irritants and allergens and their use in quantitative risk assessment. In: Contact Dermatitis, 4th ed., (Frosch PJ., Menné T, Lepoittevin J-P, eds), Berlin, Heidelberg: Springer, 179-187.

Basketter DA, McFadden J, Evans P, Andersen KE, Jowsey I. 2006. Identification and classification of skin sensitizers: Identifying false positives and false negatives. Contact Dermatitis 55(5):268-273.

Basketter DA, Andersen KE, Carola C, Van Loveren H, Boman A, Kimber I, et al. 2005. Evaluation of the skin sensitizing potency of chemicals by using the existing methods and considerations of relevance for elicitation. Contact Dermatitis 52(1):39-43.

Basketter DA, Clapp C, Jefferies D, Safford B, Ryan CA, Gerberick F, et al. 2005. Predictive identification of human skin sensitization thresholds. Contact Dermatitis 53(5):260-267.

Basketter DA, Cadby P. 2004. Reproducible prediction of contact allergenic potency using the local lymph node assay. Contact Dermatitis 50(1):15-17.

Basketter DA, Smith Pease CK, Patlewicz GY. 2003. Contact allergy: The local lymph node assay for the prediction of hazard and risk. Clinical and Experimental Dermatology 28(2):218-221.

Basketter DA, Wright ZM, Warbrick EV, Dearman RJ, Kimber I, Ryan CA, et al. 2001. Human potency predictions for aldehydes using the local lymph node assay. Contact Dermatitis 45(2):89-94.

- 106 Basketter DA, Blaikie L, Dearman RJ, Kimber I, Ryan CA, Gerberick GF, et al. 2000. Use of
107 the local lymph node assay for the estimation of relative contact allergenic potency. *Contact*
108 *Dermatitis* 42(6):344-348.
- 109 Basketter DA, Lea LJ, Cooper K, Stocks J, Dickens A, Pate I, et al. 1999. Threshold for
110 classification as a skin sensitizer in the local lymph node assay: A statistical evaluation. *Food*
111 *and Chemical Toxicology* 37(12):1167-1174.
- 112 Basketter DA, Rodford R, Kimber I, Smith I, Wahlberg JE. 1999. Skin sensitization risk
113 assessment: A comparative evaluation of 3 isothiazolinone biocides. *Contact Dermatitis*
114 40(3):150-154.
- 115 Basketter DA, Lea LJ, Dickens A, Briggs D, Pate I, Dearman RJ, et al. 1999. A comparison
116 of statistical approaches to the derivation of EC3 values from local lymph node assay dose
117 responses. *Journal of Applied Toxicology* 19(4):261-266.
- 118 Basketter DA, Roberts DW, Cronin M, Scholes EW. 1992. The value of the local lymph
119 node assay in quantitative structure-activity investigations. *Contact Dermatitis* 27(3):137-
120 142.
- 121 Betts CJ, Dearman RJ, Heylings JR, Kimber I, Basketter DA. 2006. Skin sensitization
122 potency of methyl methacrylate in the local lymph node assay: Comparisons with guinea-pig
123 data and human experience. *Contact Dermatitis* 55(3):140-147.
- 124 Betts CJ, Dearman RJ, Kimber I, Maibach HI. 2005. Potency and risk assessment of a skin-
125 sensitizing disperse dye using the local lymph node assay. *Contact Dermatitis* 52(5):268-272.
- 126 Dearman RJ, Wright ZM, Basketter DA, Ryan CA, Gerberick GF, Kimber I. 2001. The
127 suitability of hexyl cinnamic aldehyde as a calibrant for the murine local lymph node assay.
128 *Contact Dermatitis* 44(6):357-361.
- 129 DeJong WH, van Och FM, Den Hartog Jager CF, Spiekstra SW, Slob W, Vandebriel RJ, van
130 Loveren H. 2002. Ranking of allergenic potency of rubber chemicals in a modified local
131 lymph node assay. *Toxicological Science* 66(2):226-232.
- 132 Gerberick GF, Ryan CA, Dearman RJ, Kimber I. 2007. Local lymph node assay (LLNA) for
133 detection of sensitization capacity of chemicals. *Methods* 41(1):54-60.

- 134 Gerberick GF, Ryan CA, Kern PS, Schlatter H, Dearman RJ, Kimber I, et al. 2005.
135 Compilation of historical local lymph node data for evaluation of skin sensitization
136 alternative methods. *Dermatitis* 16(4):157-202.
- 137 Gerberick GF, Robinson MK, Ryan CA, Dearman RJ, Kimber I, Basketter DA, et al. 2001.
138 Contact allergenic potency: Correlation of human and local lymph node assay data.
139 *American Journal of Contact Dermatitis* 12(3):156-161.
- 140 Griem P, Goebel C, Scheffler H. 2003. Proposal for a risk assessment methodology for skin
141 sensitization based on sensitization potency data. *Regulatory Toxicology and Pharmacology*
142 38(3):269-290.
- 143 Hilton J, Dearman RJ, Harvey P, Evans P, Basketter DA, Kimber I. 1998. Estimation of
144 relative skin sensitizing potency using the local lymph node assay: A comparison of
145 formaldehyde with glutaraldehyde. *American Journal of Contact Dermatitis* 9(1):29-33.
- 146 Jowsey IR, Basketter DA, Westmoreland C, Kimber I. 2006. A future approach to measuring
147 relative skin sensitising potency: A proposal. *Journal of Applied Toxicology* 26(4):341-350.
- 148 Kimber I, Basketter DA. 1997. Contact sensitization: A new approach to risk assessment.
149 *Human and Ecological Risk Assessment (HERA)* 3(3):385-395.
- 150 Kimber I, Basketter DA, Berthold K, Butler M, Garrigue JL, Lea L, et al. 2001. Skin
151 sensitization testing in potency and risk assessment. *Toxicological Sciences* 59(2):198-208.
- 152 Kimber I, Basketter DA, Butler M, Gamer A, Garrigue JL, Gerberick GF, et al. 2003.
153 Classification of contact allergens according to potency: Proposals. *Food and Chemical*
154 *Toxicology* 41(12):1799-1809.
- 155 Kimber, I and Dearman, RJ. 1991. Investigation of lymph node cell proliferation as a
156 possible immunological correlate of contact sensitizing potential. *Food and Chemical*
157 *Toxicology* 29(2):125-129.
- 158 Kimber I, Gerberick GF, Basketter DA. 1999. Thresholds in contact sensitization:
159 Theoretical and practical considerations. *Food and Chemical Toxicology* 37(5):553-560.

- 160 Kimber I, Hilton J, Dearman RJ, Gerberick GF, Ryan CA, Basketter DA, Scholes EW,
161 Ladics GS, Loveless SE, House RV, Guy A. 1995. An international evaluation of the murine
162 local lymph node assay and comparison of modified procedures. *Toxicology* 103:63-73
- 163 Lalko J, Api AM. 2006. Investigation of the dermal sensitization potential of various
164 essential oils in the local lymph node assay. *Food and Chemical Toxicology* 44(5):739-746.
- 165 Lea LJ, Warbrick EV, Dearman RJ, Kimber I, Basketter DA. 1999. The impact of vehicle on
166 assessment of relative skin sensitization potency of 1,4-dihydroquinone in the local lymph
167 node assay. *American Journal of Contact Dermatitis* 10(4):213-218.
- 168 Loveless SE, Ladics GS, Gerberick GF, Ryan CA, Basketter DA, Scholes EW, et al. 1996.
169 Further evaluation of the local lymph node assay in the final phase of an international
170 collaborative trial. *Toxicology* 108(1-2):141-152.
- 171 Patlewicz G, Basketter DA, Smith CK, Hotchkiss SAM, Roberts DW. 2001. Skin-
172 sensitization structure-activity relationships for aldehydes. *Contact Dermatitis* 44: 331-336.
- 173 Ryan CA, Cruse LW, Skinner RA, Dearman RJ, Kimber I, Gerberick GF. 2002. Examination
174 of a vehicle for use with water soluble materials in the murine local lymph node assay. *Food*
175 *and Chemical Toxicology* 40(11):1719-1725.
- 176 Schlede E, Aberer W, Fuchs T, Gerner I, Lessmann H, Maurer T, et al. 2003. Chemical
177 substances and contact allergy - 244 Substances ranked according to allergenic potency.
178 *Toxicology* 193(3):219-259.
- 179 Schneider K, Akkan Z. 2004. Quantitative relationship between the local lymph node assay
180 and human skin sensitization assays. *Regulatory Toxicology and Pharmacology* 39(3):245-
181 255.
- 182 van Och FM, Vandebriel RJ, Prinsen MK, DeJong WH, Slob W, van Loveren H. 2001.
183 Comparison of dose-responses of contact allergens using the guinea pig maximization test
184 and the local lymph node assay. *Toxicology* 167(3):207-15. (Erratum in: *Toxicology* 2002.
185 170(3):228-230).
- 186 van Och FM, Slob W, DeJong WH, Vandebriel RJ, van Loveren H. 2000. A quantitative
187 method for assessing the sensitizing potency of low molecular weight chemicals using a local

188 lymph node assay: employment of a regression method that includes determination of the
189 uncertainty margins. Toxicology 146(1):49-59.

190 Warbrick EV, Dearman RJ, Lea LJ, Basketter DA, Kimber I. 1999. Local lymph node assay
191 responses to paraphenylenediamine: Intra- and inter-laboratory evaluations. Journal of
192 Applied Toxicology 19(4):255-260.

193 **2.4 Recommendation**

194 A preliminary review indicates that there is sufficient information available to warrant a
195 comprehensive review of the usefulness and limitations of using the LLNA to classify
196 substances for sensitization potency. Therefore, a comprehensive BRD should be prepared
197 that will evaluate the validation status the LLNA as a stand-alone assay for potency
198 determinations (including severity) for classification purposes. This BRD will serve as the
199 supporting information to be reviewed by an expert peer panel and ICCVAM.

200 ICCVAM has endorsed this activity as having high priority.

201 **3.0 NOMINATED ACTIVITY: ASSESSMENT OF THE VALIDATION** 202 **STATUS OF NON-RADIOACTIVE LLNA PROTOCOLS**

203 **3.1 Background**

204 Based on the recommendations of ICCVAM and an independent scientific peer review panel,
205 the LLNA is now accepted as an alternative to the guinea pig maximization test and the
206 Buehler test for assessing allergic contact dermatitis (ICCVAM 1999)³. Since this review,
207 there have been a number of modifications to the original protocol, as well as alternative
208 LLNA testing strategies, that have been developed. In order for these modifications to be
209 considered adequate for regulatory use, they must undergo a formal ICCVAM review of their
210 usefulness and limitations relative to the traditional LLNA.

211 One of these modifications was developed to eliminate the need for using radioactivity,
212 which is currently used in the traditional LLNA. A number of countries are either not
213 permitted to use radioactivity or its use is very limited. In this regard a number of non-

³ Available at: <http://iccvam.niehs.nih.gov/methods/immunotox/immunotox.htm>

radiolabeled endpoints are being explored to fulfill this need. Four types of methods predominate in the published literature: (1) methods that measure 5-bromo-2'-deoxyuridine (BrdU) incorporation, (2) methods employing flow cytometry to quantitate lymphocyte proliferation, (3) methods that measure cytokine release, and (4) a method that measures ear-draining lymph node weight and cell counts. The CPSC has requested that ICCVAM and NICEATM assess the current validation status of non-radioactive LLNA protocols.

3.2 Preliminary Review

NICEATM conducted a preliminary literature search⁴ to determine the availability of relevant published data. A detailed evaluation and assessment of performance will be prepared and included in a BRD following a decision to carry out the nominated activities. The preliminary search identified reports exist for each of the four methods described above. Additionally, a number of posters relevant to these types of LLNA modifications were presented at the 2007 Society of Toxicology Annual Meeting in Charlotte, NC (March 25-29, 2007), which are included in the attached reference list.

Eleven papers, all of which were published after 1998 (i.e., after the original ICCVAM evaluation of the LLNA), reported the results of investigations of the BrdU incorporation method, involving the testing of 35 different substances. Based on the listed authors and their affiliations, the reviewed studies appear have been conducted in four different laboratories (one paper by Lee, one paper by Suda, six papers by Takeyoshi, and three papers by Yamano).

Four articles and three posters, all but one published after 1998, reported results for flow cytometric methods. The studies, conducted by four different groups (two papers by the groups of Gerberick and Kimber; one paper by the group of Lee, and one paper and three posters by the group of DeGeorge), involved testing of a total of 55 different substances.

Eight papers, by five groups, reported results for methods that measured cytokine release from lymph node cell suspensions. These studies tested 20 different substances. Of these papers, seven were published after 1998.

⁴Search terms used and total number of citations identified for each method is provided in Section 3.3. References deemed to be most relevant for this analysis were reviewed further.

Four articles, all published after 1998, reported results for a method that measured draining lymph node weight and cell counts, involving the testing of 15 different substances. These studies were conducted in two different groups.

Additional searches are ongoing and relevant data will be added to the database.

3.3 References Obtained During Preliminary Review

Search terms used:

PubMed: (1) (non-RI OR nonRI OR nonrad*) AND (LLNA OR "Local Lymph Node" OR Local lymph node") - 16 citations returned

(2) (modified) AND (LLNA OR "Local Lymph Node" OR Local lymph node") - 37 citations returned

*Scopus*⁵: (TITLE-ABS-KEY(non-ri OR nonrad* OR nonri OR non-rad*) AND TITLE-ABS-KEY(llna OR "Local Lymph Node" OR "Local lymph node" OR "local lymph node")) - 18 citations returned

3.3.1 BrdU Incorporation

Lee JK, Park JH, Park SH, Kim HS, Oh HY. 2002. A nonradioisotopic endpoint for measurement of lymph node cell proliferation in a murine allergic contact dermatitis model, using bromodeoxyuridine immunohistochemistry. *Journal of Pharmacological and Toxicological Methods* 48(1):53-61.

Suda A, Yamashita M, Tabei M, Taguchi K, Vohr HW, Tsutsui N, et al. 2002. Local lymph node assay with non-radioisotope alternative endpoints. *Journal of Toxicological Sciences* 27(3):205-218.

Takeyoshi M, Noda S, Yamasaki K, Kimber I. 2006. Advantage of using CBA/N strain mice in a non-radioisotopic modification of the local lymph node assay. *Journal of Applied Toxicology* 26(1):5-9.

⁵ Abstract and citation database of research literature found at <http://www.scopus.com/scopus/home.url>.

- 265 Takeyoshi M, Iida K, Shiraishi K, Hoshuyama S. 2005. Novel approach for classifying
266 chemicals according to skin sensitizing potency by non-radioisotopic modification of the
267 local lymph node assay. *Journal of Applied Toxicology* 25(2):129-134.
- 268 Takeyoshi M, Noda S, Yamazaki S, Kakishima H, Yamasaki K, Kimber I. 2004a.
269 Assessment of the skin sensitization potency of eugenol and its dimers using a non-
270 radioisotopic modification of the local lymph node assay. *Journal of Applied Toxicology*
271 24(1):77-81.
- 272 Takeyoshi M, Noda S, Yamsaki K. 2004b. Differences in responsiveness of mouse strain
273 against p-benzoquinone as assessed by non-radioisotopic murine local lymph node assay.
274 *Experimental Animals* 53(2):171-173.
- 275 Takeyoshi M, Sawaki M, Yamasaki K, Kimber I. 2003. Assessment of statistic analysis in
276 non-radioisotopic local lymph node assay (non-RI-LLNA) with α -hexylcinnamic aldehyde as
277 an example. *Toxicology* 191(2-3):259-263.
- 278 Takeyoshi M, Yamasaki K, Yakabe Y, Takatsuki M, Kimber I. 2001. Development of non-
279 radio isotopic endpoint of murine local lymph node assay based on 5-bromo-2'-deoxyuridine
280 (BrdU) incorporation. *Toxicology Letters* 119(3):203-208.
- 281 Yamano T, Shimizu M, Noda T. 2005. Quantitative comparison of the results obtained by the
282 multiple-dose guinea pig maximization test and the non-radioactive murine local lymph-node
283 assay for various biocides. *Toxicology* 211(1-2):165-175.
- 284 Yamano T, Shimizu M, Noda T. 2004. Allergenicity evaluation of Bioban CS-1135 in
285 experimental animals. *Contact Dermatitis* 50(6):339-343.
- 286 Yamano T, Shimizu M, Noda T. 2003. Allergenicity evaluation of p-chloro-m-cresol and p-
287 chloro-m-xilenol by non-radioactive murine local lymph-node assay and multiple-dose
288 guinea pig maximization test. *Toxicology* 190(3):259-266.
- 289 3.3.2 Flow Cytometry
- 290 Gerberick GF, Cruse LW, Ryan CA. 1999. Local lymph node assay: Differentiating allergic
291 and irritant responses using flow cytometry. *Methods: A Companion to Methods in*
292 *Enzymology* 19(1):48-55.

- 293 Humphreys NE, Dearman RJ, Kimber I. 2003. Assessment of cumulative allergen-activated
294 lymph node cell proliferation using flow cytometry. *Toxicological Sciences* 73(1):80-89.
- 295 Kuhn U, Lempertz U, Knop J, Becker D. 1995. A new method for phenotyping proliferating
296 cell nuclear antigen positive cells using flow cytometry: Implications for analysis of the
297 immune response in vivo. *Journal of Immunological Methods* 179(2):215-222.
- 298 Lee JK, Park SH, Byun JA, Kim HS, Oh HY. 2004. Evaluation of lymphocyte
299 subpopulations in draining lymph node cells following allergen and irritant. *Environmental*
300 *Toxicology and Pharmacology* 17(2):95-102.
- 301 Reeder MK, Broomhead YM, DiDonato L, and DeGeorge GL. 2007. Use of an enhanced
302 local lymph node assay to correctly classify irritants and false positive substances. *The*
303 *Toxicologist CD – An official journal of the Society of Toxicology*. 96(S-1). Abstract #1136.
- 304 Reeder MK, Cerven DR, Gilotti AC, DeGeorge GL. 2006. Final validation of a flow
305 cytometry-based local lymph node assay with enhanced immunophenotypic endpoints.
306 [Poster] Presented at Society of Toxicology Annual Meeting, 5-9 March 2006, San Diego,
307 Ca. USA.
- 308 Signs, SA and DeGeorge, GL. 2004. Application of a Modified LLNA to Petroleum-based
309 Products: Dermal Sensitization Potential of Calcium Long-chain Alkyl Benzene Sulfonates.
310 [Poster] Presented at Society of Toxicology Annual Meeting, 21 -25 March 2004, Baltimore,
311 Md. USA.
- 312 3.3.3 Cytokine Release
- 313 Azam P, Peiffer JL, Ourlin JC, Bonnet PA, Tissier MH, Vian L, et al. 2005. Qualitative and
314 quantitative evaluation of a local lymph node assay based on ex vivo interleukin-2
315 production. *Toxicology* 206(2):285-298.
- 316 De Jong WH, Tentij M, Spiekstra SW, Vandebriel RJ, Van Loveren H. 2002. Determination
317 of the sensitising activity of the rubber contact sensitisers TMTD, ZDMC, MBT and DEA in
318 a modified local lymph node assay and the effect of sodium dodecyl sulfate pretreatment on
319 local lymph node responses. *Toxicology*. 176:123-134.
- 320 Hariya T, Hatao M, Ichikawa H. 1999. Development of a non-radioactive endpoint in a
321 modified local lymph node assay. *Food and Chemical Toxicology* 37(1):87-93.

- 322 Hatao M, Hariya T, Katsumura Y, Kato S. 1995. A modification of the local lymph node
323 assay for contact allergenicity screening: Measurement of interleukin-2 as an alternative to
324 radioisotope-dependent proliferation assay. *Toxicology* 98(1-3):15-22.
- 325 Jong KL, Jae HP, Eom JH, Hyung SK, Hye YO. 2005. Modulation of intracellular cytokines
326 in draining lymph node cells following allergen and irritant. *Environmental Toxicology and*
327 *Pharmacology* 20(1):225-232.
- 328 van den Berg FA, Baken KA, Vermeulen JP, Gremmer ER, van Steeg H, van Loveren H.
329 2005. Use of the local lymph node assay in assessment of immune function. *Toxicology*.
330 211(1-2):107-114.
- 331 Vandebriel RJ, De Jong WH, Hendriks JJA, Van Loveren H. 2003. Impact of exposure
332 duration by low molecular weight compounds on interferon- γ and interleukin-4 mRNA
333 expression and production in the draining lymph nodes of mice. *Toxicology* 188(1):1-13.
- 334 Vandebriel RJ, De Jong, Spiekstra SW, Van Dijk M, Fluitman A, garassen J, Van Loveren.
335 2000. Assessment of preferential T-helper 1 or T-helper 2 induction by low molecular weight
336 compounds using the local lymph node assay in conjunction with RT-PCR and ELISA for
337 interferon-gamma and interleukin-4. *Toxicology and Applied Pharmacology* 162(2):77-85.
- 338 3.3.4 Ear-draining Lymph Node Weight/Cell Counts.
- 339 De Jong WH, Tentij M, Spiekstra SW, Vandebriel RJ, Van Loveren H. 2002. Determination
340 of the sensitising activity of the rubber contact sensitizers TMTD, ZDMC, MBT and DEA in
341 a modified local lymph node assay and the effect of sodium dodecyl sulfate pretreatment on
342 local lymph node responses. *Toxicology* 176:123-134.
- 343 Ehling G, Hecht M, Heusener A, Huesler J, Gamer AO, Van Loveren H, et al. 2005a. An
344 European inter-laboratory validation of alternative endpoints of the murine local lymph node
345 assay: First round. *Toxicology* 212(1):60-68.
- 346 Ehling G, Hecht M, Heusener A, Huesler J, Gamer AO, Van Loveren H, et al. 2005b. An
347 European inter-laboratory validation of alternative endpoints of the murine local lymph node
348 assay: 2nd round. *Toxicology* 212(1):69-79.

349 Hans-Werner V, Jurgen AH. 2005. The local lymph node assay being too sensitive? Archives
350 of Toxicology 79(12):721-728.

351 3.3.5 ATP Measurement

352 Yoshimura I, Idehara K, Omori T, Kojima H, Sozu T, Arima K, et al. 2007. Validation of
353 LLNA-DA assay for assessing skin sensitization potential. The Toxicologist CD – An
354 official journal of the Society of Toxicology. 96(S-1). Abstract #1135.

355 3.3.6 CD86/CD54 Measurement

356 Ashikaga T, Kosaka N, Sono S, Hitoshi S, Hiroyuki, Itagaki H. 2007. Comparative
357 evaluation of the in vitro skin sensitization test; Human cell line activation test (h-CLAT)
358 with LLNA and human data. The Toxicologist CD – An official journal of the Society of
359 Toxicology. 96(S-1). Abstract #1144.

360 3.3.7 B Cell Measurement

361 Lalko J, Api A. 2007. Use of a B cell marker to discriminate between the irritant and
362 allergenic potential of d-Limonene. The Toxicologist CD – An official journal of the Society of
363 Toxicology. 96(S-1). Abstract #1145.

364 3.4 **Recommendation**

365 A preliminary review indicates that there is sufficient information available to warrant a
366 comprehensive review of the usefulness and limitations of non-radiolabeled modifications to
367 the LLNA. Therefore, a comprehensive BRD should be prepared to support evaluation of the
368 validation status of non-radiolabeled LLNA methods. This BRD will serve as the supporting
369 information to be reviewed by an expert peer panel and ICCVAM.

370 ICCVAM has endorsed this activity as having high priority.

**4.0 NOMINATED ACTIVITY: ASSESSMENT OF THE VALIDATION
STATUS OF THE USE OF THE LLNA TO TEST MIXTURES, AQUEOUS
SOLUTIONS AND METALS**

4.1 Background

Based on the recommendations of ICCVAM and an independent scientific peer review panel (hereafter, Panel), the LLNA is now accepted as an alternative to the guinea pig maximization test and the Buehler test for assessing allergic contact dermatitis (ICCVAM 1999)⁶. As described in the ICCVAM report, a limitation of the LLNA was its inability to identify metal salts as contact allergens. However, the Panel recognized that studies in the literature suggest that the use of alternative vehicles can improve sensitivity of the LLNA for metal salts.

Additionally, the LLNA was evaluated for testing individual chemical substances. The usefulness and limitations of the LLNA for testing mixtures, especially aqueous mixtures, has not been adequately evaluated. However, data available in the literature demonstrate the wide variability in dose-potency (up to 20-fold) of chemical substances when applied with different solvents when tested using the LLNA. Adjuvant chemicals can potentiate or diminish the strength of sensitizing ingredients.

Based on these apparent data gaps, CPSC has recently requested that ICCVAM and NICEATM assess the current validation status of the use of the LLNA to test mixtures, aqueous solutions and metals.

4.2 Preliminary Review

NICEATM conducted a preliminary search⁷ to determine the availability of published data relevant to these types of substances. A detailed evaluation and assessment of performance will be prepared and included in a BRD.

The search for LLNA studies with mixtures indicated that five papers reported results. The studies described in the papers were produced by four different groups (one paper each from

⁶Available at: <http://iccvam.niehs.nih.gov/methods/immunotox/immunotox.htm>

⁷Search terms used and total number of citations identified for each method is provided in Section 4.3. References deemed to be most relevant for this analysis were reviewed further.

the groups of Lalko, Nakamura, Selgrade; two papers from the group including Skold). A preliminary review indicated that 15 different mixtures were evaluated among these five studies. When the review was limited to the four articles published after 1998 (i.e., after the original ICCVAM evaluation of the LLNA) the number of different mixtures tested was 12.

A search for studies on metal-containing substances yielded 18 published papers produced by nine different groups (four by the group including Basketter, Gerberick, and Kimber; five by the group including Ikarashi; two by the group of Hostynek and Maibach; two by the group of Nemery; and one each by the groups of Andersen, Stokes, Noda, Ichikawa, and Tinkle). A preliminary review of these papers indicated that there were 20 different substances evaluated. When the review was limited to those 10 papers published after 1998, the total number of substances evaluated was reduced to 19 different metal-containing substances.

One paper, published in 2002, was reviewed which reported results obtained with an alternate vehicle used to test water-soluble materials. Additionally, one poster was presented at the 2007 Society of Toxicology Annual Meeting in Charlotte, NC (March 25-259, 2007) that discussed the results of studies using an alternate vehicle (Pluronic® L92 block copolymer surfactant) in the LLNA.

Additional searches in public databases (e.g., search for alternative vehicles) are ongoing and any relevant data will be added to the database.

4.3 References Obtained During Preliminary Review

4.3.1 Mixtures

Search terms used:

*Scopus*⁸: (TITLE-ABS-KEY(mixture* OR formulat*) AND TITLE-ABS-KEY(llna OR "local lymph node")) - 24 citations returned

Lalko J, Api AM. 2006. Investigation of the dermal sensitization potential of various essential oils in the local lymph node assay. Food and Chemical Toxicology 44(5):739-746.

⁸Abstract and citation database of research literature found at <http://www.scopus.com/scopus/home.url>.

- 422 Nakamura A, Kanazawa Y, Sato H, Tsuchiya T, Ikarashi Y, De Jong WH, et al. 2003.
423 Evaluation of allergic potential of rubber products: Comparison of sample preparation
424 methods for the testing of polymeric medical devices. *Journal of Toxicology - Cutaneous and*
425 *Ocular Toxicology* 22(3):169-185.
- 426 Sailstad DM, Tepper JS, Doerfler DL, Qasim M, Selgrade MK. 1994. Evaluation of an azo
427 and two anthraquinone dyes for allergic potential. *Fundamental and Applied Toxicology*
428 23(4):569-577.
- 429 Skold M, Karlberg AT, Matura M, Borje A. 2006. The fragrance chemical beta-
430 caryophyllene - Air oxidation and skin sensitization. *Food and Chemical Toxicology*
431 44(4):538-545.
- 432 Skold M, Borje A, Harambasic E, Karlberg AT. 2004. Contact allergens formed on air
433 exposure of linalool. Identification and quantification of primary and secondary oxidation
434 products and the effect on skin sensitization. *Chemical Research in Toxicology* 17(12):1697-
435 1705.
- 436 4.3.2 Metals
- 437 Search terms used:
- 438 *Scopus*⁹: (TITLE-ABS-KEY(llna OR "local lymph node") AND TITLE-ABS-
439 KEY(metal* OR aqueous)) - 37 citations returned
- 440 Andersen FA. 2005. Final report on the safety assessment of Potassium Silicate, Sodium
441 Metasilicate, and Sodium Silicate. *International Journal of Toxicology* 24(SUPPL. 1):103-
442 117.
- 443 Basketter DA, Lea LJ, Cooper KJ, Ryan CA, Gerberick GF, Dearman RJ, et al. 1999.
444 Identification of metal allergens in the local lymph node assay. *American Journal of Contact*
445 *Dermatitis* 10(4):207-212.
- 446 Clottens FL, Breysens A, De Raeve H, Demedts M, Nemery B. 1996. Assessment of the ear
447 swelling test and the local lymph node assay in hamsters. *Journal of Pharmacological and*
448 *Toxicological Methods* 35(3):167-172.

⁹Abstract and citation database of research literature found at <http://www.scopus.com/scopus/home.url>.

- 449 Dean JH, Twerdok LE, Tice RR, Sailstad DM, Hattan DG, Stokes WS. 2001. ICCVAM
450 evaluation of the murine local lymph node assay: II. Conclusions and recommendations of an
451 independent scientific peer review panel. *Regulatory Toxicology and Pharmacology*
452 34(3):258-273.
- 453 Gerberick GF, House RV, Fletcher ER, Ryan CA. 1992. Examination of the local lymph
454 node assay for use in contact sensitization risk assessment. *Fundamental and Applied*
455 *Toxicology* 19(3):438-445.
- 456 Hariya T, Hatao M, Ichikawa H. 1999. Development of a non-radioactive endpoint in a
457 modified local lymph node assay. *Food and Chemical Toxicology* 37(1):87-93.
- 458 Hostynek JJ, Maibach HI. 2003. Copper Hypersensitivity: Dermatologic Aspects - An
459 Overview. *Reviews on Environmental Health* 18(3):153-183.
- 460 Hostynek JJ, Maibach HI. 2004. Copper hypersensitivity: dermatologic aspects.
461 *Dermatologic therapy* 17(4):328-333.
- 462 Ikarashi Y, Kaniwa M, Tsuchiya T. 2002. Sensitization potential of gold sodium thiosulfate
463 in mice and guinea pigs. *Biomaterials* 23(24):4907-4914.
- 464 Ikarashi Y, Tsuchiya T, Nakamura A. 1993a. A sensitive mouse lymph node assay with two
465 application phases for detection of contact allergens. *Archives of Toxicology* 67(9):629-636.
- 466 Ikarashi Y, Tsukamoto Y, Tsuchiya T, Nakamura A. 1993b. Influence of irritants on lymph
467 node cell proliferation and the detection of contact sensitivity to metal salts in the murine
468 local lymph node assay. *Contact Dermatitis* 29(3):128-132.
- 469 Ikarashi Y, Ohno K, Tsuchiya T, Nakamura A. 1992a. Differences of draining lymph node
470 cell proliferation among mice, rats and guinea pigs following exposure to metal allergens.
471 *Toxicology* 76(3):283-292.
- 472 Ikarashi Y, Tsuchiya T, Nakamura A. 1992b. Detection of contact sensitivity of metal salts
473 using the murine local lymph node assay. *Toxicology Letters* 62(1):53-61.
- 474 Kimber I, Bentley AN, Hilton J. 1990. Contact sensitization of mice to nickel sulphate and
475 potassium dichromate. *Contact Dermatitis* 23(5):325-330.

- 476 Mandervelt C, Clottens FL, Demedts M, Nemery B. 1997. Assessment of the sensitization
477 potential of five metal salts in the murine local lymph node assay. *Toxicology* 120(1):65-73.
- 478 Ryan CA, Cruse LW, Skinner RA, Dearman RJ, Kimber I, Gerberick GF. 2002. Examination
479 of a vehicle for use with water soluble materials in the murine local lymph node assay. *Food*
480 *and Chemical Toxicology* 40(11):1719-1725.
- 481 Tinkle SS, Antonini JM, Rich BA, Roberts JR, Salmen R, DePree K, et al. 2003. Skin as a
482 route of exposure and sensitization in chronic beryllium disease. *Environmental Health*
483 *Perspectives* 111(9):1202-1208.
- 484 Yamano T, Shimizu M, Noda T. 2006. Allergenicity and cross-reactivity of naphthenic acid
485 and its metallic salts in experimental animals. *Contact Dermatitis* 54(1):25-28.

486 4.3.3 Aqueous Solutions

487 Search terms used:

488 *Scopus*¹⁰: (TITLE-ABS-KEY(llna OR "local lymph node") AND TITLE-ABS-
489 KEY(metal* OR aqueous)) - 37 citations returned

490 Ryan CA, Cruse LW, Skinner RA, Dearman RJ, Kimber I, Gerberick GF. 2002. Examination
491 of a vehicle for use with water soluble materials in the murine local lymph node assay. *Food*
492 *and Chemical Toxicology* 40(11):1719-1725.

493 Woolhiser M, Wiescinski C, Botham P, Lees D, Debruyne E, Repetto-Larsay M, et al. 2007.
494 ECPA interlaboratory study investigating the suitability of an aqueous vehicle in the mouse
495 local lymph node assay. *The Toxicologist CD – An official journal of the Society of*
496 *Toxicology*. 96(S-1). Abstract #1142.

497 4.4 **Recommendation**

498 A preliminary review indicates that there is sufficient information available to warrant a
499 comprehensive review of the usefulness and limitations of the LLNA for testing metals,
500 mixtures, and aqueous solutions. Therefore, a comprehensive BRD should be prepared that
501 will evaluate the validation status the LLNA as a stand-alone assay to test these types of

¹⁰Abstract and citation database of research literature found at <http://www.scopus.com/scopus/home.url>.

materials. This BRD will serve as the supporting information to be reviewed by an expert peer panel and ICCVAM. This review could result in expanding the applicability domain of the LLNA and therefore further reduce and refine animal use for skin sensitization testing. ICCVAM has endorsed this activity as having high priority.

5.0 NOMINATED ACTIVITY: ASSESSMENT OF THE VALIDATION STATUS OF THE LLNA LIMIT TEST

5.1 Background

Based on the recommendations of ICCVAM and an independent scientific peer review panel, the LLNA is now accepted as an alternative to the guinea pig maximization test and the Buehler test for assessing allergic contact dermatitis (ICCVAM 1999)¹¹. Since this review, there have been a number of modifications to the original protocol, as well as alternative LLNA testing strategies, that have been developed. In order to determine if these modifications are appropriate for regulatory use, their usefulness and limitations relative to the traditional LLNA must be evaluated.

One of these protocol modifications reduces the number of dose groups to two (a single high-dose group and a concurrent vehicle control group) instead of the three to five dose groups used in the traditional LLNA. This modified version of the LLNA is referred to as the “LLNA limit test” or the “cut-down screen” in the published literature. CPSC has recently requested that ICCVAM and NICEATM assess the current validation status of the LLNA limit test.

5.2 Preliminary Review

NICEATM conducted a preliminary literature search to determine the availability of published data relevant to the LLNA limit test. A detailed evaluation and assessment of comparative performance will be prepared and included in a BRD. The preliminary search indicated one report exists. The report, published in 2006, employed a retrospective analysis of an existing LLNA database of 211 different chemicals.

¹¹Available at: <http://iccvam.niehs.nih.gov/methods/immunotox/immunotox.htm>

More recently, two posters presented at the 2007 Society of Toxicology Annual Meeting in Charlotte, NC (March 25-29, 2007) discussed the LLNA limit test. Also at the SOT meeting, a presentation titled "Integrated Systems and a Modified Local Lymph Node Assay" discussed the use of the LLNA limit test to identify skin sensitizers was given by Dr. David Basketter.

5.3 References Obtained During Preliminary Review

Basketter D, Patlewicz G, Gerberick F, Ryan C, Kern P, Betts C, et al. 2007. Identification of skin sensitizing chemicals in a reduced LLNA. *The Toxicologist CD – An official journal of the Society of Toxicology*. 96(S-1). Abstract #1139.

Basketter D. 2007 Integrated systems and a modified local lymph node assay. *The Toxicologist CD – An official journal of the Society of Toxicology*. 96(S-1). Abstract #592.

Chaney J, Rayn C, Kern P, Patlewicz G, Basketter D, Betts C, et al. 2007. The impact of reducing animal numbers in the local lymph node assay. *The Toxicologist CD – An official journal of the Society of Toxicology*. 96(S-1). Abstract #1140.

Kimber I, Dearman RJ, Betts CJ, Gerberick GF, Ryan CA, Kern PS, et al. 2006. The local lymph node assay and skin sensitization: A cut-down screen to reduce animal requirements? *Contact Dermatitis* 54(4):181-185.

5.4 Recommendation

While a preliminary review suggests that limited information is currently available, the potential impact on animal savings that could be achieved by using the LLNA limit test approach warrants that a comprehensive review of the usefulness and limitations of this approach be conducted. Therefore, a comprehensive BRD should be prepared that will evaluate the validation status of this approach, and this BRD will serve as the supporting information to be reviewed by an expert peer panel and ICCVAM.

ICCVAM has endorsed this activity as having high priority.

553 6.0 SUMMARY

554 Based on the preliminary reviews described above, it appears that there is sufficient
555 information and rationale to support moving forward with a comprehensive review of these
556 modifications to the LLNA protocol and the manner in which LLNA data are used for hazard
557 classification. Therefore, a single BRD will be compiled that encompasses all four of the
558 nominated activities outlined above, and this BRD will then serve as the basis for review and
559 recommendations by an independent expert peer review panel (the Panel). The conclusions
560 and recommendations of the Panel will be forwarded to ICCVAM for consideration in
561 developing ICCVAM test method recommendations.